Peter Alfinito，博士
Peter has more than 20 years advancing drug development in the pharmaceutical industry and been with Fortrea (formerly Labcorp and Covance) for nine years. Peter has designed the clinical plan for more than 25 MASH/MASLD (metabolic dysfunction-associated steatohepatitis and metabolic dysfunction-associated steatotic liver disease) trials ranging from Phase Ib through Phase III/IV. He also brings experience in rare liver diseases such as Primary Sclerosing Cholangitis and Primary Biliary Cholangitis. Peter maintains key relationships for Fortrea with liver industry experts and networks to facilitate the smooth transition of trials, spanning the design stage to the operational stage.
